Defining N-Acetyl Cysteine as a Treatment for Inhibiting Prurogenic Stimuli
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The objective of this double-blinded placebo-controlled cross-over study is to define the
role of the over the counter agent, N-acetyl cysteine (NAC), in mitigating the development of
pruritus (skin itching). The study is designed to have all subjects treated with a seven-day
regimen of both NAC and placebo. NAC will be prescribed at a dose of 1,500 mg twice daily for
seven days. Subjects will initially be randomly assigned (1:1) to either the NAC or placebo
arm of the study, before crossing over to the opposite arm after completing a minimum of
30-day washout period. The study will encompass a period of approximately 11 weeks (about 2
and a half months).